{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:54:22Z","timestamp":1793498062018,"version":"4.5.0"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104839","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:15:39Z","timestamp":1751886939000},"page":"104839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The management of adrenocortical carcinoma in the era of precision medicine"],"prefix":"10.1016","volume":"214","author":[{"given":"F.","family":"Flauto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2025.104839_bib1","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant pheochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib2","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104839_bib3","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database","volume":"103","author":"Tella","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamasurg.2015.4516","article-title":"Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma","volume":"151","author":"Kim","year":"2016","journal-title":"JAMA Surg."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104839_bib5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib6","first-page":"161","article-title":"The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients","volume":"119","author":"Crucitti","year":"1996","journal-title":"ACC Ital. Regist. Study Group. Surg."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104839_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10434-999-0719-7","article-title":"Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma","volume":"6","author":"Schulick","year":"1999","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104839_bib11","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"ENSAT network. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104839_bib12","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/EJE-22-0173","article-title":"Assessment of prognostic factors in pediatric adrenocortical tumors: a systematic review and evaluation of a modified S-GRAS score","volume":"187","author":"Riedmeier","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib14","doi-asserted-by":"crossref","first-page":"G15","DOI":"10.1093\/ejendo\/lvae038","article-title":"International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects","volume":"190","author":"Riedmeier","year":"2024","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12020-021-02874-z","article-title":"Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?","volume":"74","author":"Grisanti","year":"2021","journal-title":"Endocrine"},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104839_bib16","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.2217\/fon-2020-0686","article-title":"The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma","volume":"16","author":"Grisanti","year":"2020","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib18","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1210\/jc.2014-3282","article-title":"Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma","volume":"100","author":"Juhlin","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.104839_bib19","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1038\/ncomms7302","article-title":"Genomic landscape of paediatric adrenocortical tumours","volume":"6","author":"Pinto","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat. Genet"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104839_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2025.104839_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2013.10.028","article-title":"Genetics and epigenetics of adrenocortical tumors","volume":"386","author":"Lerario","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104839_bib23","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","article-title":"Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors","volume":"65","author":"Tissier","year":"2005","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104839_bib24","doi-asserted-by":"crossref","first-page":"8276","DOI":"10.1158\/0008-5472.CAN-10-2014","article-title":"Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers","volume":"70","author":"Ragazzon","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/(SICI)1096-8628(19981002)79:4<253::AID-AJMG5>3.0.CO;2-N","article-title":"Molecular genetics of Wiedemann-Beckwith syndrome","volume":"79","author":"Li","year":"1998","journal-title":"Am. J. Med. Genet"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib26","first-page":"852","article-title":"Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas","volume":"77","author":"Ilvesm\u00e4ki","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib27","first-page":"1444","article-title":"Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors","volume":"78","author":"Gicquel","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib28","first-page":"28","article-title":"The product of the H19 gene may function as an RNA","volume":"10","author":"Brannan","year":"1990","journal-title":"Mol. Cell Biol."},{"issue":"6448","key":"10.1016\/j.critrevonc.2025.104839_bib29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/365764a0","article-title":"Tumour-suppressor activity of H19 RNA","volume":"365","author":"Hao","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104839_bib30","first-page":"1743","article-title":"Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction","volume":"59","author":"Feinberg","year":"1999","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104839_bib31","first-page":"2559","article-title":"Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors","volume":"82","author":"Gicquel","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1677\/jme.0.0230023","article-title":"Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line","volume":"23","author":"Logi\u00e9","year":"1999","journal-title":"J. Mol. Endocrinol."},{"issue":"7397","key":"10.1016\/j.critrevonc.2025.104839_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nature11019","article-title":"ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner","volume":"485","author":"Hao","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104839_bib34","first-page":"613","article-title":"Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors","volume":"46","author":"Goh","year":"2014"},{"key":"10.1016\/j.critrevonc.2025.104839_bib35","first-page":"5680","article-title":"PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit","volume":"5","author":"Calebiro","year":"2014"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib36","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","author":"de Reyni\u00e8s","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-08-1067","article-title":"Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling","volume":"15","author":"Giordano","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103617","article-title":"Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival","volume":"9","author":"Sun-Zhang","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104839_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"70","author":"Kulis","year":"2010","journal-title":"Adv. Genet"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104839_bib40","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","article-title":"CpG island methylator phenotype in colorectal cancer","volume":"96","author":"Toyota","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib41","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1210\/jc.2012-2993","article-title":"Identification of a CpG island methylator phenotype in adrenocortical carcinomas","volume":"98","author":"Barreau","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13148-023-01534-5","article-title":"DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma","volume":"15","author":"Kerdivel","year":"2023","journal-title":"Clin. Epigenetics"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104839_bib43","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/onc.2011.345","article-title":"A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth","volume":"31","author":"Streicher","year":"2012","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib44","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr. Rev."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104839_bib45","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2013.52.6863","article-title":"Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study","volume":"33","author":"Wasserman","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/jmg.38.1.43","article-title":"Sensitivity and predictive value of criteria for p53 germline mutation screening","volume":"38","author":"Chompret","year":"2001","journal-title":"J. Med. Genet"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104839_bib48","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2012.46.3711","article-title":"Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors","volume":"31","author":"Cust\u00f3dio","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104839_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114088","article-title":"Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma","volume":"205","author":"Scatolini","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"7-8 Pt 2","key":"10.1016\/j.critrevonc.2025.104839_bib50","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.lpm.2018.07.004","article-title":"Adrenocortical carcinoma (ACC): when and why should we consider germline testing?","volume":"47","author":"Petr","year":"2018","journal-title":"Presse Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-11-0679","article-title":"Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d\u2032etude des Tumeurs Endocrines database","volume":"166","author":"Gatta-Cherifi","year":"2012","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104839_bib52","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/BF02236860","article-title":"Adrenal masses are associated with familial adenomatous polyposis","volume":"43","author":"Smith","year":"2000","journal-title":"Dis. Colon Rectum"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ajmg.c.30064","article-title":"Risk of tumorigenesis in overgrowth syndromes: a comprehensive review","volume":"137C","author":"Lapunzina","year":"2005","journal-title":"Am. J. Med. Genet C. Semin Med. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/jc.2011-2244","article-title":"A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer","volume":"97","author":"Anselmo","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2011.12.008","article-title":"Association of adrenocortical carcinoma with familial cancer susceptibility syndromes","volume":"351","author":"Else","year":"2012","journal-title":"Mol. Cell Endocrinol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib56","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/cen.12292","article-title":"An oncocytic adrenal tumour in a patient with Birt-Hogg-Dub\u00e9 syndrome","volume":"80","author":"Raymond","year":"2014","journal-title":"Clin. Endocrinol. (Oxf. )"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib57","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40618-023-02140-1","article-title":"Outcome of brain metastases from adrenocortical carcinoma: a pooled analysis","volume":"47","author":"Turla","year":"2024","journal-title":"J. Endocrinol. Invest."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104839_bib59","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-8587(20)30218-7","article-title":"ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104839_bib60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-023-06547-z","article-title":"CXCR4-directed PET\/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology","volume":"51","author":"Dreher","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO classification of adrenal cortical tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104839_bib62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2020.10.001","article-title":"Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting","volume":"110","author":"Giordano","year":"2021","journal-title":"Hum. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib63","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.path.2019.08.005","article-title":"A diagnostic approach to adrenocortical tumors","volume":"12","author":"Hodgson","year":"2019","journal-title":"Surg. Pathol. Clin."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/106689690401200304","article-title":"Adrenocortical oncocytic tumors: report of 10 cases and review of the literature","volume":"12","author":"Bisceglia","year":"2004","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104839_bib65","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00000478-200307000-00001","article-title":"Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients","volume":"27","author":"Wieneke","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib66","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104839_bib67","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib68","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1210\/jc.2017-00254","article-title":"Performance of 18F-FDG PET\/CT in the characterization of adrenal masses in noncancer patients: a prospective study","volume":"102","author":"Guerin","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1086","key":"10.1016\/j.critrevonc.2025.104839_bib69","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170520","article-title":"Diagnostic accuracy of 18F-FDG PET or PET\/CT for the characterization of adrenal masses: a systematic review and meta-analysis","volume":"91","author":"Kim","year":"2018","journal-title":"Br. J. Radio."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib70","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104839_bib71","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr. Pr."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104839_bib72","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","article-title":"American association of endocrine surgeons guidelines for adrenalectomy: executive summary","volume":"157","author":"Yip","year":"2022","journal-title":"JAMA Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib73","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.surg.2024.09.008","article-title":"Which lymphadenectomy for adrenocortical carcinoma?","volume":"176","author":"de Ponthaud","year":"2024","journal-title":"Surgery"},{"key":"10.1016\/j.critrevonc.2025.104839_bib74","article-title":"Reoperation for recurrent adrenocortical carcinoma: a systematic review and pooled analysis of population-based studies","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Surg."},{"key":"10.1016\/j.critrevonc.2025.104839_bib75","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jss.2018.06.012","article-title":"A phase II trial of cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent adrenocortical carcinoma","volume":"232","author":"Hughes","year":"2018","journal-title":"J. Surg. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib76","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","article-title":"Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy","volume":"38","author":"Bednarski","year":"2014","journal-title":"World J. Surg."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104839_bib77","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3390\/cancers16234061","article-title":"A review on mitotane: a target therapy in adrenocortical carcinoma","volume":"16","author":"Flauto","year":"2024","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104839_bib78","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib79","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US adrenocortical carcinoma group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.critrevonc.2025.104839_bib80","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104839_bib81","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104839_bib82","unstructured":"A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane with Cisplatin\/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma with High Risk of Recurrence (ADIUVO-2 Trial) NCT03583710. 2018. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03583710."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib83","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-18-0923","article-title":"Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence","volume":"180","author":"Calabrese","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104839_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1308231","article-title":"Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma","volume":"14","author":"Wu","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib85","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1210\/jc.2012-2367","article-title":"A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma","volume":"98","author":"Habra","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib86","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","article-title":"Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma","volume":"92","author":"Sabolch","year":"2015","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib87","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1245\/s10434-018-6510-x","article-title":"Adjuvant radiation is associated with improved survival for select patients with non-metastatic adrenocortical carcinoma","volume":"25","author":"Nelson","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104839_bib88","first-page":"00654","article-title":"The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: a systematic review and meta-analysis","volume":"S1078-1439","author":"Tsuboi","year":"2024","journal-title":"Urol. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104839_bib89","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma","volume":"104","author":"Gharzai","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib90","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"German ACC study group. Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104839_bib91","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1210\/jc.2013-2281","article-title":"Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma","volume":"98","author":"Kerkhofs","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104839_bib92","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib93","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib94","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12672-016-0260-7","article-title":"German adrenocortical carcinoma study group. Salvage treatment of adrenocortical carcinoma with trofosfamide","volume":"7","author":"Kroiss","year":"2016","journal-title":"Horm. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104839_bib96","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/a-0747-5571","article-title":"Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the european network for the study of adrenal tumours registry","volume":"127","author":"Kroiss","year":"2019","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100422","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib99","first-page":"148","article-title":"Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma","volume":"36","author":"Ferrero","year":"2013","journal-title":"J. Endocrinol. Invest"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104839_bib100","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/cancers15184491","article-title":"Feasibility and activity of megestrol acetate in addition to etoposide, doxorubicin, cisplatin, and mitotane as first-line therapy in patients with metastatic\/unresectable adrenocortical carcinoma with low performance status","volume":"15","author":"Turla","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib101","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1530\/EC-19-0510","article-title":"Generation and characterization of a mitotane-resistant adrenocortical cell line","volume":"9","author":"Seidel","year":"2020","journal-title":"Endocr. Connect"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib102","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1677\/ERC-08-0224","article-title":"Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy","volume":"16","author":"Ronchi","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104839_bib103","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.3390\/cancers13215358","article-title":"Expression levels of RAD51 inversely correlate with survival of glioblastoma patients","volume":"13","author":"Morrison","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib104","doi-asserted-by":"crossref","first-page":"A129","DOI":"10.1210\/jendso\/bvab048.261","article-title":"Efficacy of treatment with PARP inhibitor and immunotherapy for aggressive adrenocortical carcinoma with cushing\u2019s syndrome refractory to treatment with EDP chemotherapy and mitotane","volume":"5","author":"Greb","year":"2021","journal-title":"J. Endocr. Soc."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104839_bib105","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/cancers13081798","article-title":"Tumor microenvironment in adrenocortical carcinoma: barrier to immunotherapy success?","volume":"13","author":"Georgantzoglou","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib106","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104839_bib107","first-page":"2194","article-title":"Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma","volume":"83","author":"Berruti","year":"1998","journal-title":"Ital. Group Study Adrenal Cancer Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.1993.11.1.161","article-title":"Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study","volume":"11","author":"Bukowski","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104839_bib109","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104839_bib110","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib111","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/ejendo\/lvad054","article-title":"Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study","volume":"188","author":"Remde","year":"2023","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib113","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104839_bib114","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020"},{"key":"10.1016\/j.critrevonc.2025.104839_bib115","first-page":"6193","article-title":"Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial","volume":"104","author":"Carneiro","year":"2019"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib116","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104839_bib117","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4128","article-title":"Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): a prospective multi-cohort basket phase II trial (CABATEN \/ GETNE-T1914)","author":"Hernando","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib118","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1908771","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538","volume":"10","author":"Klein","year":"2021","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009074","article-title":"Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort","volume":"12","author":"Patel","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104839_bib120","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1002\/onco.13798","article-title":"A phase II study of durvalumab in combination with tremelimumab in patients with rare cancers","volume":"26","author":"Edenfield","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib121","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/biomedicines9030304","article-title":"Immunotherapy in adrenocortical carcinoma: predictors of response, efficacy, safety, and mechanisms of resistance","volume":"9","author":"Araujo-Castro","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2025.104839_bib122","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4587","article-title":"Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03","volume":"31","author":"Garcia-Donas","year":"2013","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib123","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104839_bib124","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib125","article-title":"SUN-348 cabozantinib in advanced adrenocortical carcinoma: rationale and protocol of two phase II clinical trials","volume":"3","author":"Kroiss","year":"2019","journal-title":"J. Endocr. Soc."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001009","article-title":"Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma","volume":"8","author":"Bedrose","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104839_bib127","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.104839_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54661-9","article-title":"Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat. Commun."},{"issue":"_2","key":"10.1016\/j.critrevonc.2025.104839_bib129","first-page":"S498","article-title":"727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): a one-arm single-center experience","volume":"34","author":"LI","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/erc.1.01124","article-title":"Israel Glivec in Solid Tumors Study Group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R","volume":"13","author":"Gross","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib132","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2014.05.009","article-title":"Adrenocortical carcinoma: the management of metastatic disease","volume":"92","author":"Fay","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104839_bib133","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S1470-2045(24)00151-7","article-title":"Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?","volume":"25","author":"Wierman","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104839_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.667798","article-title":"Effects of sorafenib, a tyrosin kinase inhibitor, on adrenocortical cancer","volume":"12","author":"Cerquetti","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"ement_1","key":"10.1016\/j.critrevonc.2025.104839_bib135","article-title":"SAT-175 trial in progress interim report: a phase II clinical trial using single agent cabozantinib in advanced adrenocortical carcinoma","volume":"4","author":"Bedrose","year":"2020","journal-title":"J. Endocr. Soc."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104839_bib136","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"ement_1","key":"10.1016\/j.critrevonc.2025.104839_bib137","article-title":"7959 combination therapy of multi-targeted tyrosine kinase inhibitors and immune checkpoint inhibitors in advanced adrenocortical carcinoma","volume":"8","author":"Yaylaci Mert","year":"2024","journal-title":"J. Endocr. Soc."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib138","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa069","article-title":"Salvage therapy with multikinase inhibitors and immunotherapy in advanced adrenal cortical carcinoma","volume":"4","author":"Miller","year":"2020","journal-title":"J. Endocr. Soc."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104839_bib139","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-09-0717","article-title":"A phase I study of sunitinib plus bevacizumab in advanced solid tumors","volume":"15","author":"Rini","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib140","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-012-1936-5","article-title":"Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors","volume":"70","author":"Brell","year":"2012","journal-title":"Cancer Chemother. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104839_bib141","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/erc.1.01124","article-title":"Israel Glivec in Solid Tumors Study Group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R","volume":"13","author":"Gross","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104839_bib142","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1471-2407-14-561","article-title":"A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers","volume":"14","author":"Halperin","year":"2014","journal-title":"BMC Cancer"},{"issue":"ement_1","key":"10.1016\/j.critrevonc.2025.104839_bib143","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1210\/jendso\/bvab048.188","article-title":"Relacorilant with pembrolizumab: a phase 1b, open-label study of a selective glucocorticoid receptor modulator combined with a checkpoint inhibitor for patients with adrenocortical carcinoma with excess glucocorticoid production","volume":"5","author":"Habra","year":"2021","journal-title":"J. Endocr. Soc."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib144","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104839_bib145","article-title":"Alfredo Berrut EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): preliminary results of the SPENCER study","volume":"40","author":"Baudin","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104839_bib146","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib147","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib148","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104839_bib149","first-page":"232","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014"},{"key":"10.1016\/j.critrevonc.2025.104839_bib150","first-page":"2897","article-title":"Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors","volume":"22","author":"Macaulay","year":"2016"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib151","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib152","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-013-9878-1","article-title":"Everolimus therapy for progressive adrenocortical cancer","volume":"44","author":"Fraenkel","year":"2013","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104839_bib153","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib154","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0403","article-title":"PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma","volume":"13","author":"Warmington","year":"2023","journal-title":"Endocr. Connect"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib155","first-page":"1019","article-title":"Oral gossypol in the treatment of metastatic adrenal cancer","volume":"76","author":"Flack","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib156","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10637-019-00797-1","article-title":"A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma","volume":"37","author":"Xie","year":"2019","journal-title":"Invest N. Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib157","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12020-018-1795-x","article-title":"In vitro antitumor activity of progesterone in human adrenocortical carcinoma","volume":"63","author":"Fragni","year":"2019","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104839_bib158","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","article-title":"A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma","volume":"38","author":"Smith","year":"2020","journal-title":"Invest N. Drugs"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104839_bib159","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1210\/jc.2012-3261","article-title":"[\u00b9\u00b2\u00b3I]Iodometomidate imaging in adrenocortical carcinoma","volume":"98","author":"Kreissl","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib160","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2011-2765","article-title":"131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma","volume":"97","author":"Hahner","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib161","doi-asserted-by":"crossref","first-page":"e1348","DOI":"10.1210\/clinem\/dgab895","article-title":"Targeting 11-beta hydroxylase with [131I]IMAZA: A Novel Approach For The Treatment Of Advanced Adrenocortical Carcinoma","volume":"107","author":"Hahner","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib162","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/RLU.0000000000005083","article-title":"Exploring theranostic avenues in adrenocortical carcinoma using chemokine receptor and prostate-specific membrane antigen-directed PET\/CT","volume":"49","author":"Hahner","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib163","doi-asserted-by":"crossref","first-page":"dgz091","DOI":"10.1210\/clinem\/dgz091","article-title":"Treatment with 90Y\/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors","volume":"105","author":"Grisanti","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.104839_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2013.06.058","article-title":"PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target","author":"Demeure","year":"2013","journal-title":"Surgery"},{"key":"10.1016\/j.critrevonc.2025.104839_bib165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12885-016-2353-7","article-title":"Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition","volume":"16","author":"Davis","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib166","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12885-018-5129-4","article-title":"Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells","volume":"19","author":"Montgomery","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104839_bib167","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/archsurg.2009.292","article-title":"Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells","volume":"145","author":"Suh","year":"2010","journal-title":"Arch. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104839_bib168","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/cen.14629","article-title":"The role of molecular profiling in adrenocortical carcinoma","volume":"97","author":"Lippert","year":"2022","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104839_bib169","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CCO.0000000000000799","article-title":"Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021","volume":"34","author":"Grisanti","year":"2022","journal-title":"Curr. Opin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:15:33Z","timestamp":1758590133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":169,"alternative-id":["S1040842825002276"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104839","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management of adrenocortical carcinoma in the era of precision medicine","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104839"}}